SEATTLE, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Intrinsic Medicine, Inc. (Intrinsic), a therapeutics company leveraging human milk biology to transform Gut-Brain Axis (GBA) and inflammatory disorders,...
Intrinsic Medicine has signed a definitive business combination agreement with special purpose acquisition (SPAC) firm Phoenix Biotech Acquisition to create a public company.
Intrinsic Medicine couldn’t succeed down the IPO route during a rough sweeping of the biotech market this year, so the Seattle upstart is instead going with a blank-check to get its first microbiome-based candidate into a clinical trial in Australia.
Phoenix Biotechnology, Inc Receives FDA Warning Letter